Early Metabolic Abnormalities in Adolescent Girls with Polycystic Ovarian Syndrome
Overview
Authors
Affiliations
Objective: To investigate insulin sensitivity and secretion in young adolescent girls with childhood onset polycystic ovarian syndrome (PCOS) and to identify the early metabolic derangement(s).
Study Design: Twelve obese girls with PCOS (age 12.0+/-0.7 years) were compared with 10 obese nonhyperandrogenic girls (control group). The groups were matched for age, percent body fat, and abdominal fat. All subjects underwent a 3-hour hyperinsulinemic (80 mu/m(2)/min)-euglycemic clamp to determine in vivo insulin sensitivity and a 2-hour hyperglycemic clamp (225 mg/dL) to determine insulin secretion. Fasting hepatic glucose production was determined with the use of [6,6-(2)H(2)]glucose.
Results: Fasting glucose and hepatic glucose production were comparable between the 2 groups, but fasting insulin was 2-fold higher in the PCOS group. The fasting glucose to insulin ratio was lower in the PCOS group versus the control group (1.9+/- 0.3 vs 3.1+/-0.3, P =.02). During the hyperinsulinemic-euglycemic clamp, insulin sensitivity was lower in the PCOS group (1.4+/-0.2 vs 2.7+/-0.3 mg/kg/min per microu/mL, P =.002). During the hyperglycemic clamp, insulin secretion was significantly higher in the PCOS group. Insulin sensitivity correlated negatively with fasting insulin (r = -0.71, P =.0002) and positively with the fasting glucose to insulin ratio (r = 0.79, P<.0001).
Conclusion: Adolescent girls with PCOS have profound metabolic derangements detected early in the course of the syndrome, including (1) approximately 50% reduction in peripheral tissue insulin sensitivity, (2) evidence of hepatic insulin resistance, and (3) compensatory hyperinsulinemia. These observations may predict an increased risk of type 2 diabetes mellitus in adolescents with PCOS.
Lin R, Zheng S, Su H, Wang G, Li X, Lu C Phenomics. 2025; 4(6):570-583.
PMID: 40061822 PMC: 11889321. DOI: 10.1007/s43657-024-00183-9.
Liao M, Li X, Zhang H, Zhou L, Shi L, Li W Endocrine. 2023; 83(1):227-241.
PMID: 37653215 PMC: 10806039. DOI: 10.1007/s12020-023-03487-4.
Han Y, Wu H, Sun S, Zhao R, Deng Y, Zeng S Nutrients. 2023; 15(9).
PMID: 37432488 PMC: 10180647. DOI: 10.3390/nu15092230.
Assessment of Type 2 Diabetes Risk in Young Women with Polycystic Ovary Syndrome.
Livadas S, Paparodis R, Anagnostis P, Gambineri A, Bjekic-Macut J, Petrovic T Diagnostics (Basel). 2023; 13(12).
PMID: 37370962 PMC: 10297688. DOI: 10.3390/diagnostics13122067.
Metformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review.
Alfaraidi H, Samaan M Front Endocrinol (Lausanne). 2023; 13:1072879.
PMID: 36814831 PMC: 9939509. DOI: 10.3389/fendo.2022.1072879.